孟鲁司特单药或与左西替利嗪联合治疗 SARS-CoV-2。
Reposition of montelukast either alone or in combination with levocetirizine against SARS-CoV-2.
机构信息
Chichuria Institute of Medical Science & Research, Thakurpara, Chichuria, Bethuadahari-II (XVI), Nadia, West Bengal 741 126, India.
出版信息
Med Hypotheses. 2020 Nov;144:110046. doi: 10.1016/j.mehy.2020.110046. Epub 2020 Jun 28.
Abstract
It has been hypothesised that antiallergic medications (AAMs) like montelukast and levocetirizine both the two bitter chloro compounds could be repurposed either alone or combinedly as an antiviral against SARS-CoV-2, like chloroquine/hydroxychloroquine (CQ/HCQ), another two bitter chloro compounds. Both AAMs and CQ/HCQ are bitter tasted chloro compounds. Depending on their these two similar physical properties and the safety and efficacy of AAMs by controlling over post viral episodes as comparing with viral inhibitory activities including SARS-CoV-2 by CQ/HCQ, a reposition of AAMs either alone/combinedly could be rationalised as an antiviral approach to nCoV.
摘要
据推测，像孟鲁司特和左西替利嗪这样的抗过敏药物（AAMs），以及氯喹/羟氯喹（CQ/HCQ）这两种苦味氯化合物，都可以被重新利用，单独或联合作为针对 SARS-CoV-2 的抗病毒药物，就像氯喹/羟氯喹（CQ/HCQ）一样，也是两种苦味氯化合物。AAMs 和 CQ/HCQ 都是有苦味的氯化合物。基于它们这两种相似的物理特性，以及 AAMs 通过控制病毒感染后症状与 CQ/HCQ 对包括 SARS-CoV-2 在内的病毒抑制活性的安全性和有效性，AAMs 的单独或联合重新定位可能是一种合理的针对 nCoV 的抗病毒方法。
相似文献
1
Reposition of montelukast either alone or in combination with levocetirizine against SARS-CoV-2.
Med Hypotheses. 2020 Nov;144:110046. doi: 10.1016/j.mehy.2020.110046. Epub 2020 Jun 28.
2
Levocetirizine and montelukast in the COVID-19 treatment paradigm.
Int Immunopharmacol. 2022 Feb;103:108412. doi: 10.1016/j.intimp.2021.108412. Epub 2021 Dec 15.
3
Comparison of Effect of Levocetirizine or Montelukast Alone and in Combination on Symptoms of Allergic Rhinitis.
Indian J Chest Dis Allied Sci. 2016 Apr-Jun;58(2):103-5.
4
Montelukast with desloratadine or levocetirizine for the treatment of persistent allergic rhinitis.
Ann Allergy Asthma Immunol. 2006 Nov;97(5):664-71. doi: 10.1016/S1081-1206(10)61098-8.
5
Long term treatment with montelukast and levocetirizine combination in persistent allergic rhinitis: review of recent evidence.
J Indian Med Assoc. 2010 Jun;108(6):381-2.
6
Montelukast drug activity and potential against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
J Med Virol. 2021 Jan;93(1):187-189. doi: 10.1002/jmv.26299. Epub 2020 Jul 19.
7
A Randomized, Multicenter, Double-blind, Phase III Study to Evaluate the Efficacy on Allergic Rhinitis and Safety of a Combination Therapy of Montelukast and Levocetirizine in Patients With Asthma and Allergic Rhinitis.
Clin Ther. 2018 Jul;40(7):1096-1107.e1. doi: 10.1016/j.clinthera.2018.04.021. Epub 2018 Jun 24.
8
Efficacy comparison of levocetirizine vs montelukast in ragweed sensitized patients.
Ann Allergy Asthma Immunol. 2008 Sep;101(3):287-94. doi: 10.1016/S1081-1206(10)60494-2.
9
Montelukast and Coronavirus Disease 2019: A Scoping Review.
Iran J Allergy Asthma Immunol. 2021 Aug 7;20(4):384-393.
10
The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukast.
Med Hypotheses. 2020 Oct;143:109883. doi: 10.1016/j.mehy.2020.109883. Epub 2020 May 27.
引用本文的文献
1
Four chemometric models enhanced by Latin hypercube sampling design for quantification of anti-COVID drugs: sustainability profiling through multiple greenness, carbon footprint, blueness, and whiteness metrics.
BMC Chem. 2024 Mar 18;18(1):54. doi: 10.1186/s13065-024-01158-7.
2
Double-blind placebo-controlled randomized clinical trial to assess the efficacy of montelukast in mild to moderate respiratory symptoms of patients with long COVID: E-SPERANZA COVID Project study protocol.
Trials. 2022 Jan 6;23(1):19. doi: 10.1186/s13063-021-05951-w.
3
Drug Repurposing to Identify Nilotinib as a Potential SARS-CoV-2 Main Protease Inhibitor: Insights from a Computational and Study.
J Chem Inf Model. 2021 Nov 22;61(11):5469-5483. doi: 10.1021/acs.jcim.1c00524. Epub 2021 Oct 20.
本文引用的文献
1
Montelukast Reduces the Risk of Dengue Shock Syndrome in Dengue Patients.
Trop Biomed. 2018 Dec 1;35(4):1115-1122.
2
As a potential treatment of COVID-19: Montelukast.
Med Hypotheses. 2020 Sep;142:109828. doi: 10.1016/j.mehy.2020.109828. Epub 2020 May 11.
3
Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19).
Open Forum Infect Dis. 2020 Apr 15;7(4):ofaa130. doi: 10.1093/ofid/ofaa130. eCollection 2020 Apr.
4
Montelukast, an Anti-asthmatic Drug, Inhibits Zika Virus Infection by Disrupting Viral Integrity.
Front Microbiol. 2020 Jan 30;10:3079. doi: 10.3389/fmicb.2019.03079. eCollection 2019.
5
A Randomized, Multicenter, Double-blind, Phase III Study to Evaluate the Efficacy on Allergic Rhinitis and Safety of a Combination Therapy of Montelukast and Levocetirizine in Patients With Asthma and Allergic Rhinitis.
Clin Ther. 2018 Jul;40(7):1096-1107.e1. doi: 10.1016/j.clinthera.2018.04.021. Epub 2018 Jun 24.
6
Fast Disintegrating Combination Tablet of Taste Masked Levocetrizine Dihydrochloride and Montelukast Sodium: Formulation Design, Development, and Characterization.
J Pharm (Cairo). 2014;2014:568320. doi: 10.1155/2014/568320. Epub 2014 Mar 30.
7
Leukotriene receptor antagonists as maintenance and intermittent therapy for episodic viral wheeze in children.
Cochrane Database Syst Rev. 2015 Oct 19;2015(10):CD008202. doi: 10.1002/14651858.CD008202.pub2.
8
Long term treatment with montelukast and levocetirizine combination in persistent allergic rhinitis: review of recent evidence.
J Indian Med Assoc. 2010 Jun;108(6):381-2.
9
Levocetirizine inhibits rhinovirus-induced ICAM-1 and cytokine expression and viral replication in airway epithelial cells.
Antiviral Res. 2009 Mar;81(3):226-33. doi: 10.1016/j.antiviral.2008.12.001. Epub 2008 Dec 25.
10
Study of montelukast for the treatment of respiratory symptoms of post-respiratory syncytial virus bronchiolitis in children.
Am J Respir Crit Care Med. 2008 Oct 15;178(8):854-60. doi: 10.1164/rccm.200706-910OC. Epub 2008 Jun 26.
Zotero 插件